|
1.
|
Wittig JC, Bickels J, Priebat D, et al:
Osteosarcoma: a multidisciplinary approach to diagnosis and
treatment. Am Fam Physician. 65:1123–1132. 2002.PubMed/NCBI
|
|
2.
|
Ritter J and Bielack SS: Osteosarcoma. Ann
Oncol. 21(Suppl 7): vii320–vii325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Muñoz M, Rosso M and Coveñas R: A new
frontier in the treatment of cancer: NK-1 receptor antagonists.
Curr Med Chem. 17:504–516. 2010.PubMed/NCBI
|
|
4.
|
Muñoz M, Rosso M and Coveñas R: The NK-1
receptor: a new target in cancer therapy. Curr Drug Targets.
12:909–921. 2011.PubMed/NCBI
|
|
5.
|
Vanden Broeck J, Torfs H, Poels J, et al:
Tachykinin-like peptides and their receptors. A review. Ann NY Acad
Sci. 897:374–387. 1999.PubMed/NCBI
|
|
6.
|
Patacchini R and Maggi CA: Peripheral
tachykinin receptors as targets for new drugs. Eur J Pharmacol.
429:13–21. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Rollandy I, Dreux C, Imhoff V and
Rossignol B: Importance of the presence of the N-terminal
tripeptide of substance P for the stimulation of
phosphatidylinositol metabolism in rat parotid gland: a possible
activation of phospholipases C and D. Neuropeptides. 13:175–185.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Pradier L, Heuillet E, Hubert JP, et al:
Substance P-evoked calcium mobilization and ionic current
activation in the human astrocytoma cell line U 373 MG:
pharmacological characterization. J Neurochem. 61:1850–1858. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Luo W, Sharif TR and Sharif M: Substance
P-induced mitogenesis in human astrocytoma cells correlates with
activation of the mitogen-activated protein kinase signaling
pathway. Cancer Res. 56:4983–4991. 1996.
|
|
10.
|
DeFea KA, Zalevsky J, Thoma MS, et al:
Beta-arrestin-dependent endocytosis of proteinase-activated
receptor 2 is required for intracellular targeting of activated
ERK1/2. J Cell Biol. 148:1267–1281. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Palma C: Tachykinins and their receptors
in human malignancies. Curr Drug Targets. 7:1043–1052. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Muñoz M, González-Ortega A and Coveñas R:
The NK-1 receptor is expressed in human leukemia and is involved in
the antitumor action of aprepitant and other NK-1 receptor
antagonists on acute lymphoblastic leukemia cell lines. Invest New
Drugs. 30:529–540. 2012.PubMed/NCBI
|
|
13.
|
Muñoz M, Rosso M, Pérez A, et al: The NK1
receptor is involved in the antitumoural action of L-733,060 and in
the mitogenic action of substance P on neuroblastoma and glioma
cell lines. Neuropeptides. 39:427–432. 2005.PubMed/NCBI
|
|
14.
|
Muñoz M, Rosso M, Pérez A, et al:
Antitumoral action of the neurokinin-1-receptor antagonist
L-733,060 and mitogenic action of substance P on human
retinoblastoma cell lines. Invest Ophthalmol Vis Sci. 46:2567–2570.
2005.PubMed/NCBI
|
|
15.
|
Muñoz M, Rosso M and Coveñas R: The NK-1
receptor is involved in the antitumoural action of L-733,060 and in
the mitogenic action of substance P on human pancreatic cancer cell
lines. Lett Drug Des Discov. 3:323–329. 2006.PubMed/NCBI
|
|
16.
|
Muñoz M, Rosso M, Aguilar F, et al: NK-1
receptor antagonists induce apoptosis and counteract substance
P-related mitogenesis in human laryngeal cancer cell line HEp-2.
Invest New Drugs. 26:111–118. 2008.PubMed/NCBI
|
|
17.
|
Rosso M, Robles-Frias MJ, Coveñas R,
Salinas-Martín MV and Muñoz M: The NK-1 receptor is expressed in
human primary gastric and colon adenocarcinomas and is involved in
the antitumor action of L-733,060 and the mitogenic action of
substance P on human gastrointestinal cancer cell lines. Tumour
Biol. 29:245–254. 2008. View Article : Google Scholar
|
|
18.
|
Muñoz M, Pérez A, Rosso M, et al: The NK-1
receptor is expressed in human melanoma and is involved in the
antitumor action of the NK-1 receptor antagonist aprepitant on
melanoma cell lines. Lab Invest. 90:1259–1269. 2010.
|
|
19.
|
Navari RM: Fosaprepitant (MK-0517): a
neurokinin-1 receptor antagonist for the prevention of
chemotherapy-induced nausea and vomiting. Expert Opin Investig
Drugs. 16:1977–1985. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Muñoz M and Rosso M: The NK-1 receptor
antagonist aprepitant as a broad spectrum antitumor drug. Invest
New Drugs. 28:187–193. 2010.PubMed/NCBI
|
|
21.
|
Quartara L, Altamura M, Evangelista S and
Maggi CA: Tachykinin receptor antagonists in clinical trials.
Expert Opin Investig Drugs. 18:1843–1864. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Quartara L and Altamura M: Tachykinin
receptors antagonists: from research to clinic. Curr Drug Targets.
7:975–992. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Muñoz M, Pérez A, Rosso M, Zamarriego C
and Rosso R: Antitumoral action of the neurokinin-1 receptor
antagonist L-733 060 on human melanoma cell lines. Melanoma Res.
14:183–188. 2004.PubMed/NCBI
|
|
24.
|
Muñoz M, Rosso M, Casinello F and Coveñas
R: Paravertebral anesthesia: how substance P and the NK-1 receptor
could be involved in regional block and breast cancer recurrence.
Breast Cancer Res Treat. 122:601–603. 2010.PubMed/NCBI
|
|
25.
|
Muñoz M and Coveñas R: Neurokinin-1
receptor: a new promising target in the treatment of cancer. Discov
Med. 10:305–313. 2010.PubMed/NCBI
|
|
26.
|
Palma C, Bigioni M, Irrissuto C, et al:
Anti-tumour activity of tachykinin NK1 receptor antagonists on
human glioma U373 MG xenograft. Br J Cancer. 82:480–487.
2000.PubMed/NCBI
|
|
27.
|
Bigioni M, Benzo A, Irrissuto C, Maggi CA
and Goso C: Role of NK-1 and NK-2 tachykinin receptor antagonism on
the growth of human breast carcinoma cell line MDA-MB-231.
Anticancer Drugs. 16:1083–1089. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Muñoz M, Rosso M, Pérez A, et al:
Neurokinin-1 receptors located in human retinoblastoma cell lines:
antitumor action of its antagonist, L-732,138. Invest Ophthalmol
Vis Sci. 48:2775–2781. 2007.PubMed/NCBI
|
|
29.
|
Ayerza MA, Farfalli GL, Aponte-Tinao L and
Muscolo DL: Does increased rate of limb-sparing surgery affect
survival in osteosarcoma? Clin Orthop Relat Res. 468:2854–2859.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Weber K, Damron TA, Frassica FJ and Sim
FH: Malignant bone tumors. Instr Course Lect. 57:673–688. 2008.
|
|
31.
|
Hökfelt T, Pernow B and Wahren J:
Substance P: a pioneer amongst neuropeptides. J Intern Med.
249:27–40. 2001.PubMed/NCBI
|
|
32.
|
Almendro V, García-Recio S and Gascón P:
Tyrosine kinase receptor transactivation associated to G
protein-coupled receptors. Curr Drug Targets. 11:1169–1180. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Tattersall FD, Rycroft W, Cumberbatch M,
et al: The novel NK1 receptor antagonist MK-0869 (L-754,030) and
its water soluble phosphoryl prodrug, L-758,298, inhibit acute and
delayed cisplatin-induced emesis in ferrets. Neuropharmacology.
39:652–663. 2000. View Article : Google Scholar
|
